GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Issuance of Stock

Akari Therapeutics (FRA:CLA) Issuance of Stock : €11.05 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Issuance of Stock?

Akari Therapeutics's Issuance of Stock for the three months ended in Dec. 2024 was €2.99 Mil.

Akari Therapeutics's Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 was €11.05 Mil.


Akari Therapeutics Issuance of Stock Historical Data

The historical data trend for Akari Therapeutics's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Issuance of Stock Chart

Akari Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Issuance of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.59 12.65 23.78 6.43 11.28

Akari Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.22 1.59 6.59 -0.12 2.99

Akari Therapeutics Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akari Therapeutics Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics Business Description

Traded in Other Exchanges
Address
22 Boston Wharf Road, Boston, MA, USA, 02210
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Akari Therapeutics Headlines